The main reasons for this are that many patients with diabetes exhibit greatly reduced insulin responses to GIP and that elimination of GIP signaling promotes resistance to obesity in rodents [19], [20], [21], [22], suggesting that GIPR agonists would be ineffective in restoring β-cell function and may increase obesity in patients with type 2 diabetes. This evidence concerns the gene GIPR and Obesity.